Ftse Mib
34.326,90
0,51%
DAX
18.686,60
1,07%
S&P 500
5.204,32
0,32%
NASDAQ
16.353,35
0,31%
Bitcoin
61.923,71
1,20%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Akari Therapeutics PLC (AKTX) Akari Therapeutics PLC (AKTX) Notizie

AKTX

Akari Therapeutics (AKTX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AKTX
DataOraFonteTitoloSimboloCompagnia
07/05/202423:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKTXAkari Therapeutics PLC
15/03/202417:53PR Newswire (US)Kuehn Law Encourages VIVK, MINM, SDPI, and AKTX Investors to Contact Law FirmNASDAQ:AKTXAkari Therapeutics PLC
11/03/202422:25Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:AKTXAkari Therapeutics PLC
09/01/202423:25Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:AKTXAkari Therapeutics PLC
04/01/202418:34Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:AKTXAkari Therapeutics PLC
03/01/202402:06Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AKTXAkari Therapeutics PLC
01/12/202314:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AKTXAkari Therapeutics PLC
27/10/202322:15Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:AKTXAkari Therapeutics PLC
27/10/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AKTXAkari Therapeutics PLC
20/10/202322:29Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:AKTXAkari Therapeutics PLC
20/10/202322:23Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:AKTXAkari Therapeutics PLC
12/10/202322:43Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AKTXAkari Therapeutics PLC
07/06/202312:03Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:AKTXAkari Therapeutics PLC
06/06/202315:00Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AKTXAkari Therapeutics PLC
31/05/202323:08Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:AKTXAkari Therapeutics PLC
16/05/202322:05GlobeNewswire Inc.Aspira Women’s Health Names Torsten Hombeck as Chief Financial OfficerNASDAQ:AKTXAkari Therapeutics PLC
14/04/202322:07Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:AKTXAkari Therapeutics PLC
14/02/202322:14Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:AKTXAkari Therapeutics PLC
09/11/202222:13Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:AKTXAkari Therapeutics PLC
04/11/202222:01Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1/a)NASDAQ:AKTXAkari Therapeutics PLC
12/10/202222:32Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1)NASDAQ:AKTXAkari Therapeutics PLC
14/09/202218:20Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:AKTXAkari Therapeutics PLC
13/06/202213:00GlobeNewswire Inc.Akari Therapeutics Announces the Appointment of Accomplished Biotech Executive Melissa Bradford-Klug as Chief Operating Officer to Lead Business Development and Company Growth StrategiesNASDAQ:AKTXAkari Therapeutics PLC
19/05/202222:05GlobeNewswire Inc.Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual MeetingNASDAQ:AKTXAkari Therapeutics PLC
16/05/202212:43Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:AKTXAkari Therapeutics PLC
16/05/202212:00GlobeNewswire Inc.Akari Therapeutics Reports Full Year 2021 Financial Results and Highlights Clinical ProgressNASDAQ:AKTXAkari Therapeutics PLC
11/05/202213:00GlobeNewswire Inc.Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification of Clinical Deterioration Risk in COVID-19 (CASCADE) at the American Thoracic Society (ATS) 2022 Annual MeetingNASDAQ:AKTXAkari Therapeutics PLC
10/05/202213:00GlobeNewswire Inc.Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bullous Pemphigoid (BP) in JAMA DermatologyNASDAQ:AKTXAkari Therapeutics PLC
09/05/202213:00GlobeNewswire Inc.Akari Presents Results from Two Preclinical Development Programs of Long-Acting PAS-Nomacopan in Geographic Atrophy (GA) Dry Age-Related Macular Degeneration and Nomacopan in Experimental Immune-Mediated Conjunctival Disease (EIC)NASDAQ:AKTXAkari Therapeutics PLC
29/04/202223:11Edgar (US Regulatory)Notification That Form 20-f Will Be Submitted Late (nt 20-f)NASDAQ:AKTXAkari Therapeutics PLC
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AKTX

La tua Cronologia

BIT
BPE
Bper Banca
BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
NEXI
Nexi S.p.A
BIT
BAMI
Banco BPM
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
PRY
Prysmian
BIT
ENI
Eni
BIT
RACE
Ferrari NV
BIT
LDO
Leonardo
BIT
STMMI
ST Microelectronics
BIT
FBK
Finecobank
BIT
TIT
Telecom Italia
BIT
SRG
Snam
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network